1TZ Stock Chart & Stats
€7.45
-€0.20(-2.53%)
At close: 4:00 PM EST
€7.45
-€0.20(-2.53%)
Day’s Range― - ―
52-Week Range€4.38 - €9.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€161.27M
Enterprise Value€213.51
Total Cash (Recent Filing)€2.11M
Total Debt (Recent Filing)€22.77M
Price to Earnings (P/E)24.0
Beta0.83
Next Earnings
Aug 06, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding20,181,704
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)3.23
Price to Sales (P/S)1.29
P/FCF Ratio7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.33Price Target Upside105.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.37
Revenue Forecast (FY)€126.82M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe Company showed notable progress in gross margin improvement of 122 basis points Y/Y and AEBITDA margin improvement of 282 basis points Y/Y.
Operating Cash FlowOperating cash flow was $20.5M in 2024, an 82% increase Y/Y.
Bears Say
EarningsEPS of $0.04 was below our estimate and consensus of $0.08 and $0.09, respectively.
RevenueRevenue came in below our forecast and consensus due to delays in onboarding new wound care initiatives as the Company looks to improve referral processes with newer partners.
1TZ FAQ
What was InfuSystem Holdings, Inc.’s price range in the past 12 months?
InfuSystem Holdings, Inc. lowest stock price was €4.38 and its highest was €9.25 in the past 12 months.
What is InfuSystem Holdings, Inc.’s market cap?
InfuSystem Holdings, Inc.’s market cap is €161.27M.
When is InfuSystem Holdings, Inc.’s upcoming earnings report date?
InfuSystem Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 10 days.
How were InfuSystem Holdings, Inc.’s earnings last quarter?
InfuSystem Holdings, Inc. released its earnings results on May 07, 2026. The company reported €0.044 earnings per share for the quarter, beating the consensus estimate of €0.028 by €0.016.
Is InfuSystem Holdings, Inc. overvalued?
According to Wall Street analysts InfuSystem Holdings, Inc.’s price is currently Undervalued.
Does InfuSystem Holdings, Inc. pay dividends?
InfuSystem Holdings, Inc. does not currently pay dividends.
What is InfuSystem Holdings, Inc.’s EPS estimate?
InfuSystem Holdings, Inc.’s EPS estimate is 0.09.
How many shares outstanding does InfuSystem Holdings, Inc. have?
InfuSystem Holdings, Inc. has 20,181,704 shares outstanding.
What happened to InfuSystem Holdings, Inc.’s price movement after its last earnings report?
InfuSystem Holdings, Inc. reported an EPS of €0.044 in its last earnings report, beating expectations of €0.028. Following the earnings report the stock price went down -13.559%.
Which hedge fund is a major shareholder of InfuSystem Holdings, Inc.?
Currently, no hedge funds are holding shares in DE:1TZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InfuSystem Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.33 (105.82% Upside)
€15.33 (105.82% Upside)
Blogger Sentiment
Bullish
DE:1TZ Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €115.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.39%
Trailing 12-Months
Company Description
InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
1TZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced meaningful operational and financial progress with near-term headwinds. Positives include steady adjusted EBITDA (~$6.3M–$6.4M), improved gross margins, strong liquidity ($57M), rapid wound care growth (≈112% YoY to $2.1M), and a successful ERP go-live that should drive multi-quarter benefits. Offsetting these are GAAP revenue pressure from the GE Healthcare contract restructuring (quarterly reduction of ~$1.6M and an annualized ~$7.1M impact), a 17% decline in Device Solutions revenue, ERP stabilization costs and short-term cash flow/working capital pressures, and the setback on Chemo Mouthpiece coding. Overall, the company appears to be navigating a deliberate transition (mix shift toward higher-margin services and wound care) while absorbing one-time and near-term costs associated with ERP and contract restructurings.View all DE:1TZ earnings summaries1TZ Stock 12 Month Forecast
Average Price Target
€15.33
▲(105.82% Upside)
Technical Analysis
Orasure Technologies
―
Utah Medical Products
―
REPRO-MED Systems
―
Sanara MedTech
―
―









